Prevalence of chronic kidney disease in patients with psoriasis: place of genetic engineering biological therapy
- Authors: Svechnikova E.V.1,2, Zhufina S.E.1
-
Affiliations:
- Polyclinic No. 1 of the Administrative Directorate of the President of the Russian Federation
- Russian Biotechnological University
- Issue: Vol 31, No 5 (2024)
- Pages: 122-130
- Section: Clinical case
- URL: https://bakhtiniada.ru/2073-4034/article/view/267810
- DOI: https://doi.org/10.18565/pharmateca.2024.5.122-130
- ID: 267810
Cite item
Open Access
Access granted
Subscription Access
Abstract
Psoriasis is a common chronic immune-mediated disease that causes a significant burden on 125 million people worldwide. A growing body of research has led to the recognition that psoriasis is often associated with other conditions beyond the skin. Much research into the comorbidity of psoriasis has focused on the association with cardiovascular disease, cancer, infections, and psychiatric disorders, and recently there have been increasing reports of a correlation between psoriasis and kidney damage. Repeated studies have found an increased prevalence of microalbuminuria and renal failure in patients with psoriasis, and there has been a direct and inverse correlation between psoriasis, chronic kidney disease (CKD), and renal failure. Mechanisms of kidney damage may be immune-mediated, non-immune, or drug-related. The incidence, prevalence, and progression of CKD vary by race and social determinants of health, it affects ~11% of the population, and people with CKD are 5 to 10 times more likely to die prematurely than before progression to end-stage renal disease (ESRD). Additionally, psoriasis severity was associated with an increased risk of CKD and ESRD. Also, the risks of kidney damage increased in patients with other comorbid conditions (for example, psoriatic arthritis, diabetes mellitus, hypertension), which reflects the general background of systemic inflammation. In patients with psoriasis in the pediatric population, the relationship between psoriasis and kidney disease has not yet been proven.
Full Text
##article.viewOnOriginalSite##About the authors
E. V. Svechnikova
Polyclinic No. 1 of the Administrative Directorate of the President of the Russian Federation; Russian Biotechnological University
Author for correspondence.
Email: elene-elene@bk.ru
ORCID iD: 0000-0002-5885-4872
Dr. Sci. (Med.), Professor at the Department of Skin and Sexually Transmitted Diseases, Russian Biotechnological University; Head of the Department of Dermatovenereology and Cosmetology, Polyclinic No. 1 of the Administrative Directorate of the President of the Russian Federation
Russian Federation, Moscow; MoscowS. E. Zhufina
Polyclinic No. 1 of the Administrative Directorate of the President of the Russian Federation
Email: elene-elene@bk.ru
ORCID iD: 0000-0001-5694-2847
Russian Federation, Moscow
References
- Grandinetti V., Baraldi O., Comai G., at al. Renal dysfunction in psoriatic patients. G Ital Nefrol. 2020;37(1):2020-vol1.
- Jing X., Zhuyuan W., Aijun C., Jianxia X., Kun H., Ping W. Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Front Med (Lausanne). 2023 May 12;10:1175477. doi: 10.3389/fmed.2023.1175477.
- Elmets C.A., Leonardi C.L., Davis D.M.R., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073–13. doi: 10.1016/j.jaad.2018.11.058.
- Bae E.H., Kim B., Song S.H., et al. Proteinuria and Psoriasis Risk: A Nationwide Population-Based Study. J Clin Med. 2021;10:2356. doi: 10.3390/jcm10112356.
- Lee E., Han J.H., Bang C.H., et al. Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study. Sci Rep. 2019;9(1):16581. doi: 10.1038/s41598-019-53017-4.
- Acharya P., Mathur M. Association between psoriasis and celiac disease: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;pii:S0190–9622(19)33131-7
- Balwani M.R., Pasari A., Tolani P. Widening spectrum of renal involvement in psoriasis: First reported case of C3 glomerulonephritis in a psoriatic patient. Saudi J Kidney Dis Transpl. 2019;30(1):258–60.
- Berth-Jones J., Exton L.S., Ladoyanni E., et al. British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. Br J Dermatol. 2019;180:1312–38. doi: 10.1111/bjd.17587.
- Ramamoorthy S.K., Hephziba R. Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic acid and high flux dialysis Indian J Hematol Blood Transfus. 2013;29:90–2. doi: 10.1007/s12288-011-0143-6.
- Chandra T., Tabanor-Gayle J.A., Lakshminarayanan S. Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment. Cureus. 2019;11(9):e5598. doi: 10.7759/cureus.5598.
- Takeshita J., Grewal S., Langan S.M., et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol 2017;76(3):393–403. doi: 10.1016/j.jaad.2016.07.065.
- Svedbom A., Dalen J., Mamolo C., et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. Acta Derm Venereol 2015; 95(7):809–15.
- Seena P., Sandhya G., Beena N., et al. Chronic Kidney Disease in Patients with Psoriasis – A Hospital Based Cross Sectional Study. Indian Dermatology Online Journal. 2021;12(6):864-867. doi: 10.4103/idoj.IDOJ_887_20.
- Liu K.L., Tsai W.C., Tu H.P., Lee C.H. Statin Use and the Risk of Chronic Kidney Disease in Patients With Psoriasis: A Nationwide Cohort Study in Taiwan. PloS One. 2020;15(8):e0237816. doi: 10.1371/journal.pone.0237816.
- Lee S.H., Kim M., Han K.D., Lee J.H. Low hemoglobin levels and an increased risk of psoriasis in patients with chronic kidney disease. Sci Rep. 2021 Jul 20;11(1):14741. doi: 10.1038/s41598-021-94165-w.
- Bu J., Ding R., Zhou L., Chen X., Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022 Jun 10;13:880201. doi: 10.3389/fimmu.2022.880201.
- Friedland R., Kridin K., Cohen A.D., Landau D., Ben-Amitai D. Psoriasis and Renal Disorders: A Large-Scale Population-Based Study in Children and Adults. Dermatology. 2022;238(5):904–9. doi: 10.1159/000522228.
- Wild J., Keller K., Karbach S., et al. Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease. J Clin Med. 2022 Jul 26;11(15):4328. doi: 10.3390/jcm11154328.
- Munera-Campos M., Ferrandiz C., Mateo L, Prior-Espaсol A., Carrascosa J.M. Prevalence and stages of chronic kidney disease in psoriasis and psoriatic arthritis: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2021;87(2):321. doi: 10.25259/IJDVL_372_19.
- Tan Y., Huang Z., Li H., et al. Association between Psoriasis and Renal Functions: An Integration Study of Observational Study and Mendelian Randomization. Biomedicines. 2024 Jan 22;12(1):249. doi: 10.3390/biomedicines12010249.
- Maghfour J., Elliott E., Gill F., et al. Effect of biologic drugs on renal function in psoriasis patients with chronic kidney disease. J Am Acad Dermatol. 2020 May;82(5):1249–51. doi: 10.1016/j.jaad.2019.12.043.
- Chandra T., Tabanor-Gayle J., Lakshminarayanan S. Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment. Cureus. 2019;11(9):e5598. doi: 10.7759/cureus.5598.
- Cao Z., Liu Z., Zhu X., et al. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis. Renal Failure. 2022;44(1):826–30. doi: 10.1080/0886022X.2022.2073893.
Supplementary files
